Treatment of Mild Myasthenia Gravis Flare

Initial Symptomatic Treatment

The American College of Neurology recommends starting pyridostigmine immediately at 30 mg orally three times daily and gradually titrating up to a maximum of 120 mg four times daily based on symptom response, with approximately 50% of patients with mild disease showing adequate response to pyridostigmine alone 1, 2, 3
Pyridostigmine provides rapid symptomatic relief by increasing acetylcholine availability at the neuromuscular junction, and is the FDA-approved first-line treatment for myasthenia gravis 1

The American Academy of Neurology suggests that if symptoms persist despite optimal pyridostigmine dosing, prednisone 0.5-1.5 mg/kg orally daily should be added, with a positive response rate of 66-85% in myasthenia gravis 1, 2, 4
Corticosteroids become mandatory for moderate to severe disease (MGFA Class III-V) 1

The American College of Neurology recommends immediately discontinuing or avoiding medications that worsen myasthenic weakness, including β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics 1, 2, 3, 4

The American Thoracic Society recommends performing pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) to assess for respiratory compromise, even in mild flares, with daily neurologic assessment warranted during active flares to detect early signs of progression 1, 3, 4
Any dysphagia, facial weakness, or respiratory muscle involvement automatically upgrades severity to Grade 3-4 and requires hospital admission, IVIG, or plasmapheresis 1, 4